257 results
8-K
EX-99.2
CDXC
Chromadex Corp
6 Mar 24
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
4:02pm
. Statements that are not historical in nature, such as 2024 financial outlook, and which may be identified by the use of words like “expects … in older adults with MCI. Nature Communications – Berven et al., 2023 – “NR-SAFE: A Randomized, Double-Blind Safety Trial of High Dose Nicotinamide Riboside
8-K
EX-99.1
CDXC
Chromadex Corp
6 Mar 24
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
4:02pm
.
In November 2023, clinical trial published in the peer-reviewed journal, Nature Communications, found that high-dosages of Niagen® induces a potent NAD … to revenue growth, gross margin, expenses, and investment plans.
Risks that contribute to the uncertain nature of the forward-looking statements
8-K
EX-10.1
CDXC
Chromadex Corp
13 Dec 23
Entry into a Material Definitive Agreement
4:00pm
of Lender’s and entity’s officers, directors and employees from any known or unknown claims that Releasing Party now has against Lender of any nature
8-K
EX-10.2
sz477r3ezaluzetuznqt
13 Dec 23
Entry into a Material Definitive Agreement
4:00pm
8-K
EX-99.1
v9py1v8tly 2i5y
8 Nov 23
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
4:02pm
8-K
EX-99.2
mqtqqf1bmo ay
8 Nov 23
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
v3z2f1 9r
9 Aug 23
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.2
viisl 3n4
9 Aug 23
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-10.1
y7dd7ip 361q
20 Jun 23
Departure of Directors or Certain Officers
4:00pm
8-K
EX-99.2
rolxtc4julgt
10 May 23
ChromaDex Corporation Reports First Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
p8xv nb0y2ch
10 May 23
ChromaDex Corporation Reports First Quarter 2023 Financial Results
4:02pm